Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Quince Therapeutics, Inc. - Common Stock
(NQ:
QNCX
)
1.680
+0.020 (+1.20%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Quince Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research
Today 16:05 EST
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
November 11, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
This Edison International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
November 07, 2024
Via
Benzinga
This Six Flags Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
October 29, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
October 25, 2024
Via
Benzinga
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
October 25, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
October 24, 2024
Via
Benzinga
Quince Therapeutics to Participate at Upcoming Investor Conferences
October 14, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
August 19, 2024
Via
Benzinga
Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
August 16, 2024
Via
Benzinga
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
August 15, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024
August 13, 2024
Quince Therapeutics just reported results for the second quarter of 2024.
Via
InvestorPlace
Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
August 13, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia
June 25, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System
June 03, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024
May 13, 2024
Quince Therapeutics just reported results for the first quarter of 2024.
Via
InvestorPlace
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
May 13, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference
May 06, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023
April 02, 2024
Quince Therapeutics just reported results for the fourth quarter of 2023.
Via
InvestorPlace
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
April 01, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics Launches Scientific Advisory Board
February 22, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors
February 15, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 07, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics to Participate at Investor Events in January 2024
January 04, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
SHF Holdings And 3 Other Stocks Under $2 Insiders Are Buying
December 08, 2023
The Dow Jones closed higher by over 60 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Over $2M Bet On This Industrial Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
December 04, 2023
The Dow Jones closed higher by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Quince Therapeutics Completes Acquisition of EryDel S.p.A.
October 23, 2023
From
Quince Therapeutics, Inc.
Via
Business Wire
Why Glimpse Group Shares Are Trading Lower By Around 41%; Here Are 20 Stocks Moving Premarket
September 29, 2023
Gainers RVL Pharmaceuticals plc (NASDAQ: RVLP) shares rose 181.8% to $0.2201 in pre-market trading.
Via
Benzinga
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
September 28, 2023
From
Quince Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.